Fig. 2.

Concomitant loss of Men1 and Pten accelerated pancreatic neuroendocrine tumor (PanNET) development in MPR mice. a Gross pathology of pancreas in MP, MPR, MR, and PR mice at 15 or 35 weeks. Pancreas is shown with open triangle inside the mouse abdomen. b Hematoxylin and eosin (H & E) and immunohistochemical (IHC) staining of insulin and NET markers on MPR pancreatic tumors. Ki 67 index is shown. c H & E and IHC staining of glucagon of pancreas sections from MPR and MP mice of different ages. d Quantitative comparison of the ratio of the islets area per pancreas area over time in MP and MPR mice (n ≥ 10 at each time point). e Frequency of PanNETs in MPR mice at the scheduled autopsy (n = 169 in total, n = 12, 18, 23, 23, 22, 27, 23, 17, 2, 0, 2 at 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23 weeks, respectively). f Quantitative comparison of the ratio of the islets area per pancreas area over time in MPR female and male mice (n ≥ 5 at each time point of each genotype and sex). g Blood glucose levels in MPR mice (n = 133, n ≥ 11 of each time point (except n = 0 at 19, 21 and n = 2 at 23 weeks)) and MP mice (n = 133, n ≥ 11 of each time point (except n = 4 at 19, 23 and n = 0 at 21 weeks)) and h Serum insulin levels in MPR mice (n = 123, n ≥ 10 of each time point (except n = 0 at 19, 21 and n = 1 at 23 weeks)) and MP mice (n = 68, n ≥ 5 of each time point (except n = 2 at 19, n = 0 at 21 and n = 3 at 23 weeks)) over time. MPR Men1^flox/flox Pten^flox/flox RIP-Cre, MP Men1^flox/flox Pten^flox/flox, MR Men1^flox/flox RIP-Cre, PR Pten^flox/flox RIP-Cre